afaxys® pharmaceuticals
affordable access™

All information available at **www.afaxys.com**

ella®
(ulipristal acetate 30 mg tablet)

Next-Generation Prescription Strength Emergency Contraceptive

- ***ella*** **is the only 30 mg ulipristal acetate tablet currently available**

ella **is the only emergency contraceptive product that is FDA approved for use up to 5 days after unprotected sex or a known contraceptive failure[1,2]**

- Safety and tolerability established in more than 1.4 million women worldwide[3]
- Convenient, single-tablet dosing
- Affordable product, reliable supply

ORDERING INFORMATION

Order from your local drug distributor today

PACKING

Description	NDC	Dimensions
Monocarton Containing 1-tablet Blister Pack	50102-111-01	156 mm x 89 mm x 61 mm

References:
1. Glasier A, Cameron S, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta analysis. *The Lancet*. 2010; 375: 555–562.
2. Moreau C, Trussel J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. *Contraception*. 2012; 86: 673–680.
3. Levy D, Jager M, et al. Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women. *Contraception*. 2014; 89: 431–433.

To report SUSPECTED ADVERSE REACTIONS, call 1-855-888-2467 or report via the FDA Medwatch Program at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see reverse side for Important Safety Information. Also see accompanying full Prescribing Information.

ella®

(ulipristal acetate 30 mg tablet)

Important Safety Information

INDICATION

ella® is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. *ella* is not intended for routine use as a contraceptive.

IMPORTANT SAFETY INFORMATION

The most common side effects of *ella* (ulipristal acetate) tablets include headache (18%), abdominal pain (12%), nausea (12%), dysmenorrhea (9%), fatigue (6%), and dizziness (5%). *ella* is contraindicated in women with a known or suspected pregnancy, and should not replace a regular method of contraception. *ella* is not indicated for termination of an existing pregnancy. Women who become pregnant or complain of lower abdominal pain after taking *ella* should be evaluated for ectopic pregnancy. *ella* may alter the next expected menses. If menses is delayed beyond 1 week, pregnancy should be ruled out. *ella* is not recommended for use in breastfeeding women. A rapid return of fertility is likely following treatment with *ella*, therefore, a reliable barrier method of contraception should be used with subsequent acts of intercourse in that same menstrual cycle. Because *ella* and the progestin component of hormonal contraceptives both bind to the progesterone receptor, using them together could reduce their contraceptive effectiveness. After using *ella*, if a woman wishes to use hormonal contraception, she should do so no sooner than 5 days after intake of *ella*. Repeated use of *ella* within the same menstrual cycle is not recommended. Drugs or herbal products that induce CYP3A4 decrease the effectiveness of *ella*. *ella* does not protect against STI/HIV.

Please see accompanying full Prescribing Information. For more information on *ella* visit us online at www.afaxys.com or call our Afaxys Health and Safety Team at 1-855-888-2467

afaxys® pharmaceuticals
affordable access™

91114 4-2015